AA Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

AA Financial Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$435K	Hold	5,000	–	–	0.05%	157
2026 Q1	$202K	Buy	+5,000	New	+$187K	0.03%	220
2025 Q4	–	Sell	-5,000	Closed	-$416K	–	215
2025 Q3	$416K	Hold	5,000	–	–	0.08%	127
2025 Q2	$367K	Hold	5,000	–	–	0.08%	133
2025 Q1	$571K	Hold	5,000	–	–	0.14%	94
2024 Q4	$252K	Hold	5,000	–	–	0.07%	150
2024 Q3	$231K	Buy	+5,000	New	+$178K	0.07%	152

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AA Financial Advisors's CORT Position: Q2 2026 in Review

AA Financial Advisors held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 5,000 shares worth $435K. The position accounts for 0.05% of the portfolio, ranked #157.

AA Financial Advisors first reported a position in CORT in Q3 2024 and has held it in 7 quarters since. The position peaked at $571K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

AA Financial Advisors held 5,000 shares of Corcept Therapeutics worth $435K as of Q2 2026.
AA Financial Advisors left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.05% of AA Financial Advisors's portfolio in Q2 2026, its #157 holding.
AA Financial Advisors first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 7 quarters since.
AA Financial Advisors's Corcept Therapeutics position peaked at $571K in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on AA Financial Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.